Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

IFC And Nippon Chemiphar Ally In Asia, Middle East And Africa

Collaboration Aims To Reduce Reliance On Imports By Boosting Local Production Of Generics

Executive Summary

Japan’s Nippon Chemiphar and the International Finance Corporation have announced an alliance that will see the pair collaborate to boost local production of generics in Asia, the Middle East and Africa, as part of efforts to reduce reliance on imports.

You may also be interested in...



Asia Deal Watch: Astellas, GO Team Up On Targeted Cancer Therapy

Astellas subsidiary Xyphos will partner with GO to discover novel antibodies against two glycoprotein targets. SciNeuro picks up abandoned GSK programs in cardiovascular medicine for potential use in the neurodegeneration space.

Samsung Bioepis Achieves Ophthalmology Milestone With Korean Aflibercept Approval

Samsung Bioepis has celebrated becoming the first developer to obtain approvals for both Lucentis and Eylea biosimilars, after its SB15 aflibercept candidate was approved in Korea.

GGB Awards Set Stage For Milan In October

The Global Generics & Biosimilars Awards returns to Milan this October, recognizing the top achievements across the generics, biosimilars and value added medicines industries. Entries are now open and you can also book tickets to attend, both of which are free of charge.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151883

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel